Prix NuGen Medical Devices Inc (NGMDF)

Nugen Medical Devices, Inc. engages in the development of needle-free devices to administer therapeutics subcutaneously. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-05-28. The firm is engaged in marketing and selling its InsuJet needle-free injection system designed to improve the lives of millions of diabetics. Its principal business is the research, development and commercialization of needle-free injection devices and systems for the administration of subcutaneous medication. The company is developing products using its needle-free delivery technology in several fields including, but not limited to, diabetes, semaglutide, growth and fertility hormone, as well as deoxyribonucleic acid (DNA) and conventional/pediatric vaccines. The company is focusing its development efforts on needle free devices in the area of liquid jet delivery through the InsuJet platform. The firm's InsuJet technology platform is based on jet-stream administration of liquid drugs. The firm manufactures and commercializes needle-free injection systems and sells in over 40 countries globally.